ReviewIranian journal of pharmaceutical research : IJPR
Apigenin for Depression and Anxiety: A Systematic Review of Preclinical Studies.
Review in Iranian journal of pharmaceutical research : IJPR. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Context: Depression and anxiety are debilitating disorders with complex pathophysiologies associated with neurotransmitter deficits, neuroinflammation, and oxidative stress. Apigenin, a dietary flavonoid, has therapeutic potential because of its neuroprotective properties. Evidence Acquisition: We assessed the antidepressant and anxiolytic effects of apigenin in rodent models, focusing on behavioral outcomes, mechanisms involving neuroinflammation, oxidative stress, and neurotransmitter balance, and relevant molecular pathways. A systematic search of PubMed, Scopus, and Embase was conducted through July 2025. In vivo rodent studies evaluating the effects of apigenin on depression or anxiety were included. Exclusion criteria comprised studies addressing other disorders, apigenin derivatives, or non-original research. Data on study design, model, treatment, outcomes, and mechanisms were extracted. Results: Of 953 screened records, 21 studies met the inclusion criteria. Preclinical evidence consistently indicated that apigenin ameliorated depressive- and anxiety-like behaviors across diverse rodent models, frequently demonstrating effects comparable to or greater than those of conventional pharmacological treatments. Mechanistically, apigenin mediated its neuropsychological effects through multiple pathways, including reducing oxidative and nitrosative stress, inhibiting neuroinflammation, modulating monoaminergic neurotransmission, upregulating neurotrophic factors such as brain-derived neurotrophic factor (BDNF) and cAMP response element-binding protein (CREB), and regulating energy metabolism and neurogenesis. Apigenin exhibited a favorable safety profile across all included studies, even at high doses. Conclusions: In rodent models, apigenin exhibits substantial antidepressant and anxiolytic effects through complex mechanisms involving redox modulation, anti-inflammatory activity, neurotransmitter regulation, and neurotrophic support. These findings indicate that apigenin warrants further translational investigation and potential therapeutic development for treating depression and anxiety disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.